The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to ...

UK-based biopharmaceutical company AstraZeneca has announced a $3.5bn investment to expand its research and manufacturing ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...

Meanwhile, Bayer had less good fortune in Q3 as CEO Bill Anderson acknowledged that the company’s earnings were “not pretty.” ...

On the heels of releasing its latest financial statement, Vancouver-based biotechnology company Absci announced it has met its first milestone in its collaboration with pharmaceutical giant AstraZenec ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

One investigation discussed during the call involves sales reps in China allegedly changing genetic testing results to secure reimbursement for Tagrisso.

AstraZeneca Plc isn’t the only health-care company facing compliance questions in China as concern continued to swirl about a ...

The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...

London-listed drugmaker AstraZeneca said its plan to invest 450 million pounds ($576.7 million) in Britain for vaccine ...